Phio Pharmaceuticals shares surge 13.86% intraday on PH-762 trial results showing 85% cSCC response rate and no serious adverse events ahead of FDA talks.

Phio Pharmaceuticals surged 13.86% intraday after announcing participation in a Renmark Financial Communications virtual roadshow to discuss its INTASYL siRNA platform and PH-762 Phase 1b trial results. The trial reported 85% pathological response rates in cutaneous squamous cell carcinoma at the highest dose cohort, with no dose-limiting toxicities or serious adverse events across 22 patients. The company highlighted plans for FDA engagement in Q2 2026 and cash runway extending into mid-2027, reinforcing confidence in its immuno-oncology pipeline. The roadshow, featuring a CEO presentation and Q&A, likely amplified investor optimism about the therapeutic’s potential and strategic direction.